表紙
市場調査レポート

Sevion Therapeutics, Inc.の製品パイプライン分析

Sevion Therapeutics, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321986
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
Sevion Therapeutics, Inc.の製品パイプライン分析 Sevion Therapeutics, Inc. - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 24 Pages
概要

Sevion Therapeutics, Inc.は米国に本社を置く製薬企業で、真核生物翻訳開始因子5A(eIF5A)技術を利用し、細胞死と細胞生存の制御をおこなう製品および技術を提供しています。対象領域は癌、炎症などです。

当レポートでは、Sevion Therapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Sevion Therapeutics, Inc. の基本情報

  • Sevion Therapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Sevion Therapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Sevion Therapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Sevion Therapeutics, Inc. :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Sevion Therapeutics, Inc. :薬剤プロファイル

  • SNS-01T
  • insulin human
  • SVN-001
  • SVN-002
  • Monoclonal Antibodies to Modulate GPCR for Cancer
  • Monoclonal Antibody to Modulate Ion Channel for Pain

Sevion Therapeutics, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Sevion Therapeutics, Inc. :最新のパイプライン情報

Sevion Therapeutics, Inc. :開発が休止されたプロジェクト

Sevion Therapeutics, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07902CDB

Summary

Global Markets Direct's, 'Sevion Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Sevion Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sevion Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Sevion Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Sevion Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Sevion Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Sevion Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Sevion Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Sevion Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Sevion Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sevion Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Sevion Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sevion Therapeutics, Inc. Snapshot
    • Sevion Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Sevion Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sevion Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Sevion Therapeutics, Inc. - Pipeline Products Glance
    • Sevion Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sevion Therapeutics, Inc. - Drug Profiles
    • insulin human
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVN-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVN-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Modulate GPCR for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Modulate Ion Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sevion Therapeutics, Inc. - Pipeline Analysis
  • Sevion Therapeutics, Inc. - Pipeline Products by Target
  • Sevion Therapeutics, Inc. - Pipeline Products by Molecule Type
  • Sevion Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Sevion Therapeutics, Inc. - Dormant Projects
  • Sevion Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • SNS-01T
  • Sevion Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sevion Therapeutics, Inc., Key Information
  • Sevion Therapeutics, Inc., Key Facts
  • Sevion Therapeutics, Inc. - Pipeline by Indication, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sevion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sevion Therapeutics, Inc. - Preclinical, 2015
  • Sevion Therapeutics, Inc. - Discovery, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Target, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Sevion Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Sevion Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Sevion Therapeutics, Inc. - Discontinued Pipeline Products, 2015
  • Sevion Therapeutics, Inc., Subsidiaries

List of Figures

  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Sevion Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Sevion Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Sevion Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top